Dr Rita Bottino, Director of Islet Programs at Imagine Pharma, discusses the need for regulatory reform in islet allotransplantation for type 1 diabetes. Islet allotransplantation – the transplantation of isolated pancreatic islets from a deceased donor to a living recipient with type 1 diabetes – has emerged as a promising therapy for patients with type 1 […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!